文献速递临床试验与 GCP流行病学与生物统计

替罗非班用于无大中血管闭塞的卒中患者

Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
PubMed 文献 · N Engl J Med · 2023-01-01

在中国开展的多中心试验中,纳入无大中血管闭塞、NIHSS评分≥5分且至少一肢中度至重度无力的缺血性卒中患者606例(替罗非班组)和571例(阿司匹林组)。替罗非班组90天改良Rankin量表评分0或1分的比例为29.1%,阿司匹林组为22.2%(校正风险比1.26;95%CI 1.04至1.53;P=0.02)。替罗非班组症状性颅内出血发生率为1.0%,阿司匹林组为0%。

要点

  • 替罗非班组90天mRS 0或1分比例29.1%,阿司匹林组22.2%,校正RR 1.26(95%CI 1.04-1.53;P=0.02)。
  • 替罗非班组症状性颅内出血发生率1.0%,阿司匹林组0%。
  • 两组死亡率相似。

核心结论

  • 在近期起病或症状进展且无大中脑血管闭塞的异质性卒中患者中,静脉替罗非班较阿司匹林更可能获得极佳结局。
  • 颅内出血发生率低,但替罗非班组略高。

研究设计与样本

  • 中国多中心试验,纳入无大中血管闭塞、NIHSS评分≥5分且至少一肢中度至重度无力的缺血性卒中患者。
  • 606例分配至替罗非班组,571例分配至阿司匹林组。
  • 替罗非班组接受静脉替罗非班(加口服安慰剂),阿司匹林组接受口服阿司匹林100mg/天(加静脉安慰剂)治疗2天,之后所有患者口服阿司匹林至第90天。

主要发现

  • 90天mRS评分0或1分的比例:替罗非班组29.1% vs 阿司匹林组22.2%(校正风险比1.26;95%CI 1.04至1.53;P=0.02)。
  • 次要终点结果与主要分析结果总体不一致。
  • 两组死亡率相似。
  • 症状性颅内出血发生率:替罗非班组1.0% vs 阿司匹林组0%。

关键数值与推荐

  • 主要疗效终点为90天极佳结局,定义为改良Rankin量表评分0或1分(范围0[无症状]至6[死亡])。
  • 次要终点包括90天功能独立和生活质量评分。
  • 主要安全终点为死亡和症状性颅内出血。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied. METHODS: In a multicenter trial in China, we enrolled patients with ischemic stroke without occlusion of large or medium-sized vessels and with a National Institutes of Health Stroke Scale score of 5 or more and at least one moderately to severely weak limb. Eligible patients had any of four clinical presentations: ineligible for thrombolysis or thrombectomy and within 24 hours after the patient was last known to be well; progression of stroke symptoms 24 to 96 hours after onset; early neurologic deterioration after thrombolysis; or thrombolysis with no improvement at 4 to 24 hours. Patients were assigned to receive intravenous tirofiban (plus oral placebo) or oral aspirin (100 mg per day, plus intravenous placebo) for 2 days; all patients then received oral aspirin until day 90. The primary efficacy end point was an excellent outcome, defined as a score of 0 or 1 on the modified Rankin scale (range, 0 [no symptoms] to 6 [death]) at 90 days. Secondary end points included functional independence at 90 days and a quality-of-life score. The primary safety end points were death and symptomatic intracranial hemorrhage. RESULTS: A total of 606 patients were assigned to the tirofiban group and 571 to the aspirin group. Most patients had small infarctions that were presumed to be atherosclerotic. The percentage of patients with a score of 0 or 1 on the modified Rankin scale at 90 days was 29.1% with tirofiban and 22.2% with aspirin (adjusted risk ratio, 1.26; 95% confidence interval, 1.04 to 1.53, P = 0.02). Results for secondary end points were generally not consistent with the results of the primary analysis. Mortality was similar in the two groups. The incidence of symptomatic intracranial hemorrhage was 1.0% in the tirofiban group and 0% in the aspirin group. CONCLUSIONS: In this trial involving heterogeneous groups of patients with stroke of recent onset or progression of stroke symptoms and nonoccluded large and medium-sized cerebral vessels, intravenous tirofiban was associated with a greater likelihood of an excellent outcome than low-dose aspirin. Incidences of intracranial hemorrhages were low but slightly higher with tirofiban. (Funded by the National Natural Science Foundation of China; RESCUE BT2 Chinese Clinical Trial Registry number, ChiCTR2000029502.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Zi W, Song J, Kong W, et al. Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. N Engl J Med. 2023. PMID: 37256974. doi:10.1056/NEJMoa2214299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。